Deep brain stimulation market seen reaching $4.52 billion by 2030

The Business Research Company projects the global deep brain stimulation systems market will grow from $2.77 billion in 2025 to $4.52 billion by 2030, driven by rising neurological disorder cases and broader use of neuromodulation therapies. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Deep brain stimulation systems are gaining importance as neurological disorder cases rise worldwide. - The market’s projected jump to $4.52 billion by 2030 signals growing demand for implantable therapies that can be adjusted and reversed. - The forecast points to wider use of deep brain stimulation beyond traditional movement disorders.

What happened: - The Business Research Company released a 2026 market report on the global deep brain stimulation systems market. - The report estimates the market will rise from $2.77 billion in 2025 to $3.05 billion in 2026. - The report forecasts the market will reach $4.52 billion by 2030. - The report is titled "The Business Research Company's Deep Brain Stimulation Systems Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - A free sample of the report is available. - The full market report is also available.

The details: - Deep brain stimulation systems use implanted electrodes to deliver electrical impulses to targeted brain areas. - The treatment helps regulate abnormal brain activity and improve symptoms linked to neurological conditions. - The technology is used in neurosurgery to modulate neural function in a reversible and adjustable way. - The report links recent growth to rising prevalence of neurological disorders, broader clinical acceptance of neuromodulation therapies, technological progress in implantable devices, growth in specialized neurology centers and better long-term patient outcomes. - The report says future growth will be supported by investment in next-generation neurostimulation devices, demand for more personalized neurological treatments, expansion of DBS indications beyond movement disorders, AI-driven programming and remote patient monitoring. - The report highlights adaptive DBS systems, image-guided electrode placement, rechargeable neurostimulators, personalized neuromodulation therapies and minimally invasive implantation methods as emerging trends. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market growth case is being driven by a larger patient pool and by technology that makes DBS easier to tailor to individual patients. - Expansion beyond movement disorders suggests DBS is moving from a niche procedure toward broader neurological use. - The regional split points to a mature North American market and faster adoption potential in Asia-Pacific. - World Federation of Neurology data released in October 2023 said more than 40% of the global population currently suffers from some neurological condition, and that burden is expected to nearly double by 2050.

What's next: - The report expects investment to keep shifting toward smarter, more personalized and more remotely managed DBS systems. - Growth in Asia-Pacific could narrow the gap with North America if adoption accelerates during the forecast period. - The company is offering more information through its market report materials and sales contacts. - Follow-on updates may focus on technology changes such as adaptive DBS and AI-assisted programming.

The bottom line: - Deep brain stimulation is emerging as a faster-growing segment in neurological care, with demand rising as treatment options broaden and the global burden of neurological disease increases.